These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33499345)

  • 1. Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.
    Mori T; Kumagai K; Nasu K; Yoshizawa T; Kuwano K; Hamada Y; Kanazawa H; Suzuki R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor-infiltrating lymphocytes and PD-L1 expression in esophageal squamous cell carcinoma.
    Hu J; Toyozumi T; Murakami K; Endo S; Matsumoto Y; Otsuka R; Shiraishi T; Iida S; Morishita H; Makiyama T; Nishioka Y; Uesato M; Hayano K; Nakano A; Matsubara H
    Cancer Med; 2024 Sep; 13(17):e70179. PubMed ID: 39264227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.
    Habu T; Kumagai S; Bando H; Fujisawa T; Mishima S; Kotani D; Nakamura M; Hojo H; Sakashita S; Kinoshita T; Yano T; Mitsunaga S; Nishikawa H; Koyama S; Kojima T
    J Gastroenterol; 2024 Sep; 59(9):798-811. PubMed ID: 38819498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8
    Fukuoka E; Yamashita K; Tanaka T; Sawada R; Sugita Y; Arimoto A; Fujita M; Takiguchi G; Matsuda T; Oshikiri T; Nakamura T; Suzuki S; Kakeji Y
    Anticancer Res; 2019 Aug; 39(8):4539-4548. PubMed ID: 31366557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
    Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
    Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
    Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
    Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
    Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
    Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
    Sugawara K; Fukuda T; Murakami C; Oka D; Yoshii T; Amori G; Ishibashi K; Kobayashi Y; Hara H; Kanda H; Motoi N
    Cancer Sci; 2024 Aug; 115(8):2819-2830. PubMed ID: 38693726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-A
    Zhang D; Jiang D; Jiang L; Ma J; Wang X; Xu X; Chen Z; Jiang M; Ye W; Wang J; Meng W; Qiu W; Hou Y; Huang J; Jiao Y; Liu Y; Liu Z
    Br J Cancer; 2024 Jul; 131(1):184-195. PubMed ID: 38762674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Chen TC; Wu CT; Wang CP; Lou PJ; Ko JY; Chang YL
    Oral Oncol; 2020 Dec; 111():104945. PubMed ID: 32769036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.